LMR Partners’s MapLight Therapeutics MPLT Stock Holding History

LMR Partners’s Portfolio MPLT Stock Details MPLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$203K	Hold	10,000	–	–	﹤0.01%	1196
2025 Q4	$176K	Buy	+10,000	New	+$168K	﹤0.01%	1297

Other funds holding MPLT

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LMR Partners's MPLT Position: Q1 2026 in Review

LMR Partners held its MapLight Therapeutics (MPLT) position steady in Q1 2026 at 10,000 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #1196.

LMR Partners first reported a position in MPLT in Q4 2025 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

LMR Partners held 10,000 shares of MapLight Therapeutics worth $203K as of Q1 2026.
LMR Partners left its MapLight Therapeutics share count unchanged in Q1 2026.
MapLight Therapeutics made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1196 holding.
LMR Partners first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 2 quarters since.
81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.